In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Glepaglutide | Synthetic analog Apraglutide | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic analog | |
| Area | Gut and digestion | Gut and digestion | |
| Evidence | |||
| Amount of evidence | 86 | 110 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 21 (21 in people) | 21 (20 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 11 · 2 active | None registered | |
Shared outcomes
From the regulatory data of each peptide.
Its most advanced trial is in phase 3. The FDA, the EMA and the other sources we use show no approval (as of 27 Oct 2026).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Glepaglutide | Apraglutide |
|---|---|---|
| Adverse eventsWhole body | 1313 | 11101 |
| Gastrointestinal protectionGastrointestinal |
PepBank is a research reference. Talk to a doctor before you use any peptide.
Its most advanced trial is in phase 3. The FDA and the other sources we use show no approval (as of 27 Oct 2026).
55
431231 |
| Intestinal growth and absorptionGastrointestinal | 21129 | 66 |
|---|
| Gastrointestinal adverse eventsGastrointestinal | 66 | 1010 |
|---|
| PharmacokineticsPharmacology | 55 | 16691 |
|---|
| Intensive care and hospital outcomesGastrointestinal | 66 | 77 |
|---|
| Gut microbiotaGastrointestinal | 22 | 66 |
|---|
| Gastrointestinal motilityGastrointestinal | 66 | 11 |
|---|
| Receptor activity and mechanismGastrointestinal | 22 | 44 |
|---|
| Body weightMetabolic and weight | 11 | 33 |
|---|
| MortalityWhole body | 11 | 22 |
|---|
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 11 trials, ranked by phase, then posted results and enrollment: 3 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)
Zealand Pharma106 participants4 Oct 2018 to 26 Jul 2022
Short Bowel Syndrome
Zealand Pharma12 participants10 Aug 2021 to 5 Sept 2023
Short Bowel Syndrome
Zealand Pharma150 participants7 May 2019 to 30 Apr 2026
Short Bowel Syndrome
No registered trial that tests Apraglutide found in ClinicalTrials.gov.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Glepaglutide | Apraglutide |
|---|---|---|
| Intensive care and hospital outcomesGastrointestinalCompared as: value in the arm that got the peptide, in % | No comparable result 4 randomized-trial results measure it in another way or another unit. | −25.5% Mean relative change in weekly parenteral support volume · apraglutide, overall population, week 24 Placebo, overall population, week 24: −12.5% 24 weeksn = 1632026 |
| Intestinal growth and absorptionGastrointestinalCompared as: value in the arm that got the peptide, in g/day | −592 g/day Change in faecal wet weight output · 1 mg glepaglutide, adjusted mean change from baseline Dose studied: 1 mg daily3 weeksn not reported2019 | No randomized trial result 6 results from other study designs. |
No comparable result
4 randomized-trial results measure it in another way or another unit.
−25.5%
Mean relative change in weekly parenteral support volume · apraglutide, overall population, week 24
Placebo, overall population, week 24: −12.5%
24 weeksn = 1632026
−592 g/day
Change in faecal wet weight output · 1 mg glepaglutide, adjusted mean change from baseline
Dose studied: 1 mg daily3 weeksn not reported2019
No randomized trial result
6 results from other study designs.